

Prescribing Clinical Network

Policy Statement	Overactive Bladder Pathway
Policy No:	PCN 79-2013
Date of Issue	27 th November 2013
Review Date:	November 2015 <i>(Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)</i>
<p>Recommendations: The PCN supported the overactive bladder drug choice pathway which is based on the new NICE guidance and available on the Prescribing Advisory Database. The PCN does not routinely support the use of solifenacin</p>	
<p>Key Considerations:</p> <ul style="list-style-type: none"> • NICE CG 171 Urinary Incontinence in Women • The PCN were not able to recommend the use of solifenacin based on cost effectiveness noting the NICE statement (CG171) that there is a lack of evidence to show a difference in clinical effectiveness between OAB drugs and that relative cost effectiveness is determined mostly by the difference in the cost between the drugs. • The PCN were not presented with any additional clinical evidence that had not been considered by NICE in CG171 • Request to acute trust DTCs to remove solifenacin from their formularies – for discussion and agreement locally. 	
Date taken to Prescribing Clinical Network	27 th November 2013
Agreed by PCN members	December 2013

Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG), North East Hampshire & Farnham CCG, Crawley CCG and Horsham & Mid-Sussex CCG